CLAIMS:

1. A liquid pharmaceutical formulation comprising a GLP-1 analogue consisting of the amino acid sequence set forth in SEQ ID NO:3, wherein the GLP-1 analog is at a concentration of 50 μg/ml to 2 mg/ml, and wherein the liquid pharmaceutical formulation is at a pH of between 6.5±0.5 and 7.5±0.5 and comprises a) histidine HCl at a concentration of about 10 mM±10%, b) a sugar-based tonicity agent at a concentration of from 100 mM to 450 mM c) polysorbate 20 at a concentration of from 0.005 to 0.05% and d) an amino acid excipient at a concentration of from 5 mM to 75 mM.

2. The liquid pharmaceutical formulation of claim 1, wherein the sugar-based tonicity agent is mannitol at a concentration of from 150 mM to 350 mM.

3. The liquid pharmaceutical formulation of claim 1, wherein the sugar-based tonicity agent is sucrose at a concentration of from 145 mM to 440 mM.

4. The liquid pharmaceutical formulation of claim 1, wherein the amino acid excipient is methionine at a concentration of from 5 mM to 25 mM.

5. The liquid pharmaceutical formulation of claim 1, wherein the amino acid excipient is proline at a concentration of from 25 mM to 75 mM.

6. The liquid pharmaceutical formulation of claim 1, wherein the GLP-1 analogue is at a concentration of from 100 μg/ml to 1 mg/ml.

7. The liquid pharmaceutical formulation of claim 1, wherein the GLP-1 analogue is at a concentration of from 100 μg/ml to 500 μg/ml.

8. The liquid pharmaceutical formulation of claim 1, wherein the GLP-1 analogue is at a concentration of 300 μg/ml±20%.

9. The liquid pharmaceutical formulation of claim 1, wherein the liquid pharmaceutical formulation is at pH 7.0±0.5.

10. The liquid pharmaceutical formulation of claim 1, wherein the GLP-1 analogue consists of the amino acid sequence set forth in SEQ ID NO:3 at a concentration of from 50

µg/ml to 2 mg/ml, wherein the liquid pharmaceutical formulation comprises histidine-HCl at a concentration of about 10 mM, mannitol at a concentration of about 275 mM, methionine at a concentration of about 10 mM and polysorbate 20 at a concentration of about 0.02%.

11. The liquid pharmaceutical formulation of claim 1, wherein the GLP-1 analogue consists of the amino acid sequence set forth in SEQ ID NO:3 at a concentration of from 50 µg/ml to 2 mg/ml, wherein the liquid pharmaceutical formulation comprises histidine-HCl at a concentration of about 10 mM, sucrose at a concentration of about 235 mM, methionine at a concentration of about 10 mM and polysorbate 20 at a concentration of about 0.02%.

12. The liquid pharmaceutical formulation of claim 1, wherein the liquid pharmaceutical formulation is selected from the group consisting of:
a. a liquid pharmaceutical formulation comprising a GLP-1 analogue consisting of an amino acid sequence as set forth in SEQ ID NO:3, wherein the GLP-1 analogue is at a concentration of from 100 µg/ml to 1 mg/ml and wherein the liquid pharmaceutical formulation comprises histidine-HCl at a concentration of 10 mM, mannitol at a concentration of 275 mM, methionine at a concentration of 10 mM and polysorbate 20 at a concentration of 0.02%, and;
b. a liquid pharmaceutical formulation comprising a GLP-1 analogue consisting of an amino acid sequence as set forth in SEQ ID NO:3, wherein the GLP-1 analogue is at a concentration of from 100 µg/ml to 1 mg/ml and wherein the liquid pharmaceutical formulation comprises histidine-HCl at a concentration of 10 mM, sucrose at a concentration of 233 mM (8%), methionine at a concentration of 10 mM and polysorbate 20 at a concentration of 0.02%.

13. The liquid pharmaceutical formulation of claim 12, wherein the liquid pharmaceutical formulation is at pH 7.0±0.5.

14. A single-dose or multiple-dose container comprising the liquid pharmaceutical formulation of claim 12.

15. A liquid pharmaceutical formulation comprising a GLP-1 analogue consisting of an amino acid sequence as set forth in SEQ ID NO:3, wherein the GLP-1 analogue is at a

concentration of from 50 μg/ml to 2 mg/ml and wherein the liquid pharmaceutical formulation is at a pH of between of 6.5±0.5 and 7.5±0.5 and comprises:

a. histidine-HCl at a concentration of about 10 mM±10%, mannitol at a concentration of from 100 mM to 350 mM, and polysorbate 20 at a concentration of from 0.01 to 0.03% (w/v);

b. histidine-HCl at a concentration of about 10 mM±10%, mannitol at a concentration of 165 mM±10%, and polysorbate 20 at a concentration of from 0.01 to 0.03% (w/v);

c. histidine-HCl at a concentration of 10 mM±10%, mannitol at a concentration of 275 mM±10%, and polysorbate 20 at a concentration of from 0.01 to 0.03% (w/v);

d. histidine-HCl at a concentration of 10 mM±10%, mannitol at a concentration of 275 mM±10%, polysorbate 20 at a concentration of from 0.01 to 0.03% (w/v) and methionine at a concentration of from 5 mM to 25 mM;

e. histidine-HCl at a concentration of 10 mM±10%, mannitol at a concentration of 165 mM±10%, polysorbate 20 at a concentration of from 0.01 to 0.03% (w/v) and methionine at a concentration of from 5 mM to 25 mM;

f. histidine-HCl at a concentration of 10 mM±10%, mannitol at a concentration of 275 mM±10%, polysorbate 20 at a concentration of from 0.01 to 0.03% (w/v) and proline at a concentration of from 25 mM to 75 mM;

g. histidine-HCl at a concentration of 10 mM±10%, mannitol at a concentration of 165 mM±10%, polysorbate 20 at a concentration of from 0.01 to 0.03% (w/v) and proline at a concentration of from 25 mM to 75 mM;

h. histidine-HCl at a concentration of 10 mM±10%, sucrose at a concentration of from 145 mM to 450 mM, and polysorbate 20 at a concentration of from 0.01 to 0.03% (w/v);

i. histidine-HCl at a concentration of about 10 mM±10%, sucrose at a concentration of about 235 mM±10%, and polysorbate 20 at a concentration of from 0.01 to 0.03% (w/v);

j. histidine-HCl at a concentration of about 10 mM±10%, sucrose at a concentration of about 290 mM±10%, and polysorbate 20 at a concentration of from 0.01 to 0.03% (w/v);

k. histidine-HCl at a concentration of about 10 mM±10%, sucrose at a concentration of about 235 mM±10%, polysorbate 20 at a concentration of from 0.01 to 0.03% (w/v) and methionine at a concentration of from 5 mM to 25 mM;

l. histidine-HCl at a concentration of about 10 mM±10%, sucrose at a concentration of about 290 mM±10%, polysorbate 20 at a concentration of from 0.01 to 0.03% (w/v) and methionine at a concentration of from 5 mM to 25 mM;

m. histidine-HCl at a concentration of about 10 mM±10%, sucrose at a concentration of about 235 mM±10%, polysorbate 20 at a concentration of from 0.01 to 0.03% (w/v) and proline at a concentration of from 25 mM to 75 mM, or;

n. histidine-HCl at a concentration of about 10 mM±10%, sucrose at a concentration of about 290 mM±10%, polysorbate 20 at a concentration of from 0.01 to 0.03% (w/v) and proline at a concentration of from 25 mM to 75 mM.